gip and glp-1 Biology of Incretins: Dual GLP-1/GIP Agonist | Tirzepatide
Description
March 10, 2026 As GLP-1 indications expand, accurate risk assessment depends on confirming diagnosis, companion therapy signals, and persistence in Prescription Data
[18] Other prokinetic options include low-dose erythromycin for short-term use, and domperidone, which is available in the US only through an FDA Investigational New Drug application
Iepsen et al
Another important benefit involves cardiovascular risk factors
Meanwhile, some studies on GLP-1RA's anti-inflammatory effects in T2D patients have been conducted
